In this presentation from The Landscape of Cancer Research: Advances in Immuno-Oncology, Twist Bioscience highlights a multifaceted approach to antibody discovery targeting Dickkopf-1 (DKK1), a protein implicated in tumor progression and immune evasion. The talk, titled “Identification of Dickkopf-1 (DKK1) Antibodies Utilizing a Multi-Faceted Discovery Strategy,” outlines how Twist’s synthetic DNA and antibody libraries enabled the rapid development of high-affinity antibodies with therapeutic potential.

The presentation showcases how Twist’s platform integrates high-throughput screening, precision gene synthesis, and rational design to accelerate the development of novel immunotherapies. By targeting DKK1—a promising but challenging cancer antigen—Twist demonstrates the power of its end-to-end antibody discovery workflow for advancing immuno-oncology research and supporting the development of next-generation cancer therapies.